SWOT Analysis of AstraZeneca 2026: Strengths, Weaknesses, Opportunities and Threats

This is a SWOT analysis of AstraZeneca PLC, written in September 2026 as a sample for an MBA strategic management module. The four quadrants are built on the company's own filings for the year ended 31 December 2025: the FY and Q4 2025 results announcement of 10 February 2026 and the Annual Report and Form 20-F Information 2025, filed with the SEC on 24 February 2026. Where the H1 and Q2 2026 results of 27 July 2026 have overtaken a point, the 2026 position is given beside it. Figures are FY2025, in US dollars as reported, unless another period is named.

SWOT sorts what a company controls from what it does not; the second section shows why that sorting is harder for a pharmaceutical company than it looks.

AstraZeneca's 2025 pulls two ways: Total Revenue rose 8 percent at constant exchange rates to $58,739 million and oncology reached 44 percent of the company, while Farxiga, the largest medicine, was one year from its expected US loss of exclusivity (AstraZeneca, 2026b), China grew only 4 percent and net debt stood at $23,374 million (AstraZeneca, 2026a).

What Does AstraZeneca Sell, and How Much Did It Sell in 2025?

AstraZeneca sells prescription medicines in oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology (R&I), vaccines and immune therapies (V&I) and rare disease. In FY2025 Total Revenue was $58,739 million, up 9 percent as reported and 8 percent at constant exchange rates; Product Sales were $55,573 million, Alliance Revenue $3,067 million and Collaboration Revenue $99 million (AstraZeneca, 2026a).

AstraZeneca Total Revenue by therapy area, FY2025

Chart data

Item	Value (bn USD)
Oncology	25.6 bn USD
Cardiovascular, Renal and Metabolism	12.9 bn USD
Rare Disease	9.1 bn USD
Respiratory and Immunology	8.9 bn USD
Vaccines and Immune Therapies	1.3 bn USD
Other Medicines	1 bn USD

By therapy area, Oncology was $25,619 million (44 percent of the total, up 14 percent at CER), CVRM $12,861 million (22 percent, up 2 percent), Rare Disease $9,126 million (16 percent, up 4 percent), R&I $8,866 million (15 percent, up 12 percent), V&I $1,268 million (2 percent, down 14 percent) and Other Medicines $999 million (down 8 percent). By region, the United States was $25,450 million (43 percent, up 10 percent), Europe $12,739 million (22 percent, up 1 percent), Emerging Markets excluding China $8,649 million (15 percent, up 22 percent), China $6,654 million (11 percent, up 4 percent) and Established Rest of World $5,247 million (9 percent, up 6 percent); the announcement sums that table as "Growth in Total Revenue across all major geographic regions" (AstraZeneca, 2026a). Both tables add up to the total; check that before you quote either.

The Annual Report names the five largest products: Farxiga ($8,492 million), Tagrisso ($7,254 million), Imfinzi ($6,063 million), Ultomiris ($4,718 million) and Calquence ($3,518 million). It also counts 16 blockbusters, each above $1 billion of annual sales (AstraZeneca, 2026b). Together the five were $30,045 million, 51 percent of Total Revenue (our sum); three are oncology medicines, and the largest is not.

For a UK reader, one point of housekeeping: AstraZeneca is a UK company headquartered on the Cambridge Biomedical Campus, listed in London and Stockholm, with its ordinary shares on the New York Stock Exchange since 2 February 2026 in place of its earlier Nasdaq ADS listing; it reports in US dollars, and the United States is 43 percent of its revenue. Its annual report is one document that serves as both the UK Annual Report and the SEC's Form 20-F (AstraZeneca, 2026b; 2026g). Do not convert the dollar figures; our guide to reading an annual report for a case study shows how to cite a combined annual report and 20-F in Harvard.

Read more MBA assignment samples, or see how we approach an MBA assignment. For the same four quadrants on a company whose largest product line is half of its revenue, read our SWOT analysis of Apple.

What Does an AstraZeneca SWOT Analysis Show in 2026?

The strengths are oncology at 44 percent of revenue and a 31 percent core operating margin; the weaknesses are net debt of $26,912 million by June 2026 and Farxiga past US exclusivity; the opportunities are the $80 billion ambition and rare disease; the threats are generics, pricing and trial outcomes (AstraZeneca, 2026a; 2026i).

AstraZeneca SWOT analysis, FY2025 figures and H1 2026 results

Helpful Harmful Internal

Strengths Internal, helpful

• Oncology 25.6bn dollars, 44 percent of revenue, up 14 percent at CER
• Sixteen blockbuster medicines; five multi-blockbusters in oncology
• Core R&D 13.8bn dollars, 24 percent of revenue; 197 pipeline projects
• Core operating margin 31 percent in FY2025, 34 percent in H1 2026
• Operating cash inflow 14.6bn dollars, up 2.7bn on 2024

Weaknesses Internal, harmful

• Net debt 23.4bn to 26.9bn dollars in the six months to June 2026
• Farxiga 8.5bn dollars, about 14 percent of revenue; generics in the US, UK, Japan and China
• Reported operating margin 23 percent against core 31 percent
• Alliance Revenue 3.1bn dollars on medicines with a profit share paid away
• China 11 percent of revenue and down 5 percent at CER in H1 2026

External

Opportunities External, helpful

• 80bn dollars of Total Revenue and 20 new medicines by 2030 (the company's ambition)
• Rare Disease up 11 percent at CER in H1 2026
• Emerging Markets excluding China up 22 percent at CER in FY2025
• 50bn dollar US and 15bn dollar China investment plans to 2030
• More than twenty high-value readouts due in 18 months (the company's statement)

Threats External, harmful

• Farxiga US loss of exclusivity; multiple generics launched in Q2 2026
• China volume-based procurement and generic competition
• The October 2025 US pricing agreement, now visible in gross margin
• Medicare price negotiation: Farxiga from 2026, Calquence from 2027
• Trial outcomes: CARDIO-TTRansform and SERENA-4 primary endpoints not met

In short, oncology carries the company while its largest medicine loses exclusivity, and the first half of 2026 confirmed both halves. Total Revenue rose 6 percent at CER to $30,672 million, "with double-digit growth in Oncology and Rare Disease offsetting headwinds from Farxiga US loss of exclusivity and China volume-based procurement", and the core operating margin rose to 34 percent (AstraZeneca, 2026i). The grid above carries one sourced fact per bullet; the four sections after it carry the evidence.

Notice how often one event appears in two quadrants. Farxiga's exclusivity ended because a legal term ran out, which the company did not decide, so generic entry is a threat. The decision to let one medicine grow to about 14 percent of revenue was the company's, so the concentration is a weakness. The same split runs through China.

What Are AstraZeneca's Strengths?

AstraZeneca's strengths are oncology, scale in individual medicines, R&D depth and margin. Oncology revenue was $25,619 million in FY2025, up 14 percent at constant exchange rates; sixteen medicines each sold more than $1 billion; core R&D was $13,822 million, 24 percent of revenue; and core operating profit was $18,478 million, a 31 percent margin (AstraZeneca, 2026a; 2026b).

AstraZeneca Total Revenue and core operating profit, FY2021 to FY2025

Chart data

Point (bn USD)	Total Revenue	Core operating profit
FY2021	37.4 bn USD	9.9 bn USD
FY2022	44.4 bn USD	13.4 bn USD
FY2023	45.8 bn USD	14.5 bn USD
FY2024	54.1 bn USD	16.9 bn USD
FY2025	58.7 bn USD	18.5 bn USD

1. Oncology at scale and still growing. Oncology Total Revenue was $25,619 million, 44 percent of the company, up 14 percent at CER; in the first half of 2026 it was $14,124 million, 46 percent of the company, up 15 percent (AstraZeneca, 2026a; 2026i). The Annual Report credits "five multi-blockbuster medicines: Tagrisso, Imfinzi, Calquence, Lynparza and Enhertu" (AstraZeneca, 2026b). In FY2021 the oncology line was $13,048 million (AstraZeneca, 2022), so it has almost doubled in four years (our comparison). A line growing at 14 percent on a $25 billion base adds more revenue in a year than the whole V&I line is worth, which is why it can absorb the Farxiga loss.
2. Sixteen blockbusters, five of them above $3.5 billion. Farxiga, Tagrisso, Imfinzi, Ultomiris and Calquence were $30,045 million between them, 51 percent of Total Revenue (our sum from AstraZeneca, 2026b). Breadth means no single generic entry ends the growth story; the largest of the five, the exposed one, gets its own line in the weaknesses.
3. R&D at 24 percent of revenue, with a late-stage pipeline that converts. Core R&D was $13,822 million, 24 percent of Total Revenue (AstraZeneca, 2026a). The pipeline "comprises 197 projects, with 176 in the clinical phase of development", including 20 new molecular entities "in pivotal trials or under regulatory review, up from 19 at the end of 2024"; in 2025, 20 projects were discontinued, "11 due to safety or efficacy, eight due to strategic shifts and one due to regulatory reasons" (AstraZeneca, 2026b). The results announcement counts 16 positive Phase 3 readouts and 43 approvals in major regions in the year (AstraZeneca, 2026a). A pipeline is only a strength if it converts; the readout and approval counts are the conversion evidence, and the discontinuation count is the cost of it.
4. A core operating margin that has held above 30 percent for four years. Core operating margin was 26.5 percent in FY2021, then 30.1, 31.7, 31 and 31 percent, on core operating profit that rose from $9,928 million to $18,478 million (AstraZeneca, 2022; 2023; 2024; 2025; 2026a). The first half of 2026 was better still, 35 percent in the first quarter and 34 percent for the half (AstraZeneca, 2026h; 2026i). The word "core" carries a caveat, taken up in the weaknesses.
5. Cash generation that funds the plan. Net cash inflow from operating activities was $14,575 million in FY2025, up $2,714 million on 2024, against capital expenditure of $3,270 million and a dividend of $3.20 per share (AstraZeneca, 2026a). The half-year figure was $6,224 million (AstraZeneca, 2026i). Operating cash covers the capital programme; what it does not cover is the first weakness.

Five-year margins, each from its own results announcement (AstraZeneca, 2022; 2023; 2024; 2025; 2026a); the reported column is here so the gap argued next is visible.

What Are AstraZeneca's Weaknesses?

The weaknesses are debt, concentration and the gap between two profit numbers. Net debt rose from $23,374 million in December 2025 to $26,912 million in June 2026. Farxiga, the largest medicine, is past US exclusivity and fell 11 percent at CER in H1 2026. Reported operating margin was 23 percent against core 31 percent (AstraZeneca, 2026a; 2026b; 2026i).

The four numbers the weaknesses rest on

Net debt at 30 June 2026

26.9 bn USD 23.4bn at 31 December 2025 and 25.9bn at 31 March 2026.

Farxiga, the largest-selling medicine, FY2025

8.5 bn USD About 14 percent of Total Revenue, our calculation; US exclusivity ended, generics from Q2 2026.

Reported operating margin, FY2025

23% Core margin 31 percent; the 4.7bn gap is mostly amortisation and impairment of intangibles.

China Total Revenue, H1 2026

3.5 bn USD 11 percent of revenue; down 5 percent at CER in the half and 13 percent in Q2.

1. Net debt rising through 2026. Net debt was $23,374 million at 31 December 2025, $25,944 million at 31 March 2026 and $26,912 million at 30 June 2026, a rise of $3,538 million in the half (AstraZeneca, 2026a; 2026h; 2026i). The half-year cash flow explains the rise. Net cash inflow from operating activities fell by $875 million to $6,224 million. The largest single line in the financing table was dividends paid of $3,288 million; business development took a $1,104 million upfront payment to CSPC Pharmaceuticals; new long-term loans of $1,990 million were below repayments of $2,450 million; and the shortfall was bridged with $2,407 million of commercial paper. Of the $3,538 million rise, $2,015 million was cash flow and $1,698 million was non-cash, mostly new lease liabilities, less $175 million of exchange movements (AstraZeneca, 2026i, Tables 21 and 22; the lease reading is ours). On 24 August 2026 the company priced EUR 2.55 billion of Eurobonds "for general corporate purposes" (AstraZeneca, 2026l). Net debt now exceeds a full year of core operating profit (our comparison), and the dividend ($3,288 million) was as large a call on cash as all purchases of intangible assets ($3,333 million, the CSPC payment among them).
2. One medicine at about 14 percent of revenue, and it is the exposed one. Farxiga's $8,492 million is about 14 percent of Total Revenue (our calculation), larger than any of the company's oncology medicines. US Farxiga sales were $1,730 million in 2025, down 1 percent, "as the prior year benefitted from the launch of an authorised generic" (AstraZeneca, 2026c). In the first half of 2026 Farxiga Product Sales were $3,998 million, down 11 percent at CER, with the United States at $668 million, down 17 percent, and the note "Multiple generics launched in Q2 2026". The other three regional rows carry a generic note too, for China ("VBP implementation in China in Q1 2026"), the UK ("generic entry in the UK in Q3 2025") and Japan ("Generic T2D entry in Japan in Q4 2025") (AstraZeneca, 2026i). BioPharmaceuticals, $11,151 million and 36 percent of revenue, fell 5 percent at CER in the half; Oncology and Rare Disease, 62 percent of revenue between them, grew enough to offset the fall in the rest (AstraZeneca, 2026i).
3. Reported profit is eight points below core. Reported operating profit was $13,743 million, a 23 percent margin, against core operating profit of $18,478 million, 31 percent. The $4,735 million difference is $4,327 million of intangible asset amortisation and impairments, $237 million of restructuring and $171 million of other items (AstraZeneca, 2026a, Table 10). The first half of 2026 repeats the pattern, 24 percent against 34 percent (AstraZeneca, 2026i). The intangibles are largely bought pipeline: Alexion "was incorporated into the Group's results from 21 July 2021" (AstraZeneca, 2023), and the FY2021 reported margin of 2.8 percent against a core 26.5 percent shows the size of that adjustment. A marker will ask which margin you used and why; the answer is that "core" describes the operating business and "reported" describes what the acquisitions cost.
4. Partnered medicines with a profit share paid away. Alliance Revenue was $3,067 million, up 39 percent as reported, "including $1,798 million from Enhertu and $673 million from Tezspire" (AstraZeneca, 2026b), and $1,699 million in the first half of 2026, up 31 percent as reported. The half-year announcement explains why that growth is worth less per dollar: medicines with profit-sharing arrangements (it names Lynparza, Enhertu, Datroway and Tezspire) reduce gross margin "because AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its collaboration partners" (AstraZeneca, 2026i). Two of the five multi-blockbusters, Lynparza and Enhertu, are shared, and the partners' decisions on them are outside the company's control.
5. China is shrinking at the price line. China was $6,654 million in 2025, 11 percent of revenue, up 4 percent; then $3,510 million in the first half of 2026, down 5 percent at CER, with the second quarter down 13 percent (AstraZeneca, 2026a; 2026i). The company calls China its second-largest market (AstraZeneca, 2026e). A market that is second-largest and falling is a weakness in the accounts; the policy behind it is a threat and gets one sentence there.

What Opportunities Does AstraZeneca Have?

The opportunities are those the company has put numbers on: $80 billion of revenue and at least 20 new medicines by 2030. Rare Disease grew 11 percent at CER in H1 2026, Emerging Markets excluding China grew 22 percent in FY2025, and the company counts more than twenty high-value readouts due in 18 months (AstraZeneca, 2026b; 2026i).

1. The 2030 ambition, stated as the company's own. "By 2030, we aim to launch at least 20 new medicines and achieve $80 billion in Total Revenue with sustained growth thereafter", and by the end of 2025 the Annual Report counts "9 NMEs delivered against our Ambition 2030" (AstraZeneca, 2026b). The half-year announcement says the company is "on track" and that the ambition "assumes successes and setbacks" (AstraZeneca, 2026i). From $58,739 million, $80 billion needs about 6.4 percent a year compounded over five years (our calculation), and the FY2026 guidance is that "Total Revenue is expected to increase by a mid-to-high single-digit percentage" (AstraZeneca, 2026a; 2026i).
2. Rare disease. Rare Disease Total Revenue was $9,126 million in FY2025, up 4 percent at CER, then $2,420 million in the first quarter of 2026, up 15 percent, and $4,911 million for the half, up 11 percent (AstraZeneca, 2026a; 2026h; 2026i). A line accelerating from 4 to 11 percent while the largest line falls is where the replacement revenue comes from.
3. Rebuilding CVRM behind Farxiga. The half-year announcement reports "eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension" (AstraZeneca, 2026i), and the CSPC notice of 30 January 2026 is headed "AstraZeneca enhances its weight management portfolio" and calls CVRM "a key growth driver for the Company" (AstraZeneca, 2026f). Neither carries a sales figure yet, which is why this opportunity cannot carry 2026 and oncology and rare disease must.
4. Emerging markets outside China. Emerging Markets excluding China grew 22 percent at CER in FY2025 to $8,649 million and 10 percent in the first half of 2026 to $4,809 million (AstraZeneca, 2026a; 2026i); the Annual Report counts "six world-first approvals for our medicines in emerging markets" in 2025 (AstraZeneca, 2026b). This is the region replacing the growth China used to supply.
5. The US investment plan. "In the US, we plan to invest $50 billion in manufacturing and R&D, including our $4.5 billion facility in Virginia", followed by $2 billion in Maryland; the same page says the United States "is projected to represent approximately 50% of our Total Revenue by 2030" (AstraZeneca, 2026b). Manufacturing inside the largest market answers the tariff window in the threats before it closes.
6. China as a source of science, not only a market. On 29 January 2026 the company announced $15 billion of investment in China through 2030, noting four manufacturing sites that supply "over 70 markets" and "16 global licensing agreements with 15 Chinese partners" since 2023 (AstraZeneca, 2026e). The next day it licensed the eight CSPC obesity and type 2 diabetes programmes in item 3, with exclusive rights outside China, a $1.2 billion upfront payment and milestones of up to $3.5 billion (AstraZeneca, 2026f). The sales line in China is shrinking; the pipeline sourced from China is still growing.
7. Readouts and approvals in the next 18 months. The half-year announcement reports "six key positive Phase III programmes and eight first approvals in major markets" in the half and "more than twenty high-value readouts due over the next 18 months" (AstraZeneca, 2026i). Readouts are options, and the threats quadrant shows the other outcome.
8. A New York listing without leaving London. The American Depositary Share listing on Nasdaq ceased on 30 January 2026 and the ordinary shares began trading on the New York Stock Exchange on 2 February 2026, with the London and Stockholm listings unchanged and the stated purpose of "enabling more US investors to participate" (AstraZeneca, 2026d; 2026g). For a company expecting half its revenue from the United States, a wider US shareholder base is a capital-structure opportunity, not a relocation.

What Threats Does AstraZeneca Face in 2026?

Seven threats are documented in the filings: Farxiga's US loss of exclusivity, volume-based procurement in China, the October 2025 US agreement and its three-year tariff term, Medicare price negotiation under the IRA, trial outcomes, competition in the filing's own words, and antitrust litigation over Soliris. Each is given below in the filing's wording (AstraZeneca, 2026b; 2026i; 2026m).

1. Generic entry against Farxiga. The half-year headline names "headwinds from Farxiga US loss of exclusivity", and the US row of the Farxiga table says "Multiple generics launched in Q2 2026" (AstraZeneca, 2026i). The event is external; its size is in the weaknesses, because the concentration was the company's own choice.
2. Volume-based procurement in China. Farxiga's Emerging Markets row reads "Affected by generic competition and VBP implementation in China in Q1 2026", and the gross-margin note lists "Pricing headwinds, including those driven by loss of exclusivity and VBP in China" (AstraZeneca, 2026i). The recommendations treat China as a volume market with a price set by procurement.
3. The US pricing agreement and its tariff term. "In October, we announced an agreement with the US administration which provides greater clarity around pricing and a three-year exemption from tariffs" (AstraZeneca, 2026b), and the half-year gross-margin drivers include "implementation of the US government agreement announced in 2025" (AstraZeneca, 2026i). The pricing side is already visible in gross margin; the exemption is a window, answered in the opportunities. The policy behind both is a PESTEL factor and is not re-argued here.
4. Medicare price negotiation. "Farxiga was selected for the first round of Medicare price negotiations under the IRA", and its Maximum Fair Price "has now taken effect in 2026, coinciding in the same year as the expected US loss of market exclusivity"; "Calquence was selected for the second round of price negotiations in 2025. Its Maximum Fair Price for Medicare will take effect in 2027" (AstraZeneca, 2026b). The second round reaches into oncology, where the strengths sit; Calquence is the fifth-largest medicine.
5. Trial outcomes. The half-year milestone table lists seven Phase III readouts since the previous results, four with the primary endpoint met and three not (our count from Table 1), among them Wainua in CARDIO-TTRansform, which "did not meet the primary efficacy endpoint", and Ultomiris in TMA-313 (AstraZeneca, 2026i). The Ultomiris result matters most here because it sits under the rare-disease opportunity: the trial "did not achieve statistical significance for the primary endpoint of event-free survival through 26 weeks compared to placebo" (AstraZeneca, 2026j). Two more setbacks followed the half: on 17 August 2026 the company said it "is discontinuing the eVOLVE-Lung02 Phase III trial" on its data monitoring committee's recommendation (AstraZeneca, 2026k), and on 14 September 2026 SERENA-4 "did not meet the primary endpoint of progression-free survival (PFS), however a numerical improvement was observed" (AstraZeneca, 2026m).
6. Competition, in the filing's own words. The Annual Report's viability statement lists among the principal risks "Pricing, affordability, access, competitive pressures and failures or delays in the quality or execution of the Group's commercial strategies" (AstraZeneca, 2026b), and the half-year Tagrisso table, on the second-largest medicine, notes a "More competitive environment in China in a slowing EGFRm TKI market" and, in Established Rest of World, a "Recent competitor entrant" (AstraZeneca, 2026i). The oncology line the recommendations rely on is not uncontested.
7. Antitrust litigation over Soliris. The Annual Report lists a class action filed in April 2025 in which "the plaintiff alleges that AstraZeneca violated federal and state antitrust and business practices laws by obtaining improper patents for Soliris, delaying biosimilar entry and improperly extending Soliris' market exclusivity", and records that in December 2025 the court "partially granted AstraZeneca's motion to dismiss" (AstraZeneca, 2026b). It is an allegation, not a finding, and it sits under the therapy area that is 16 percent of revenue.

What Should AstraZeneca Do, Based on This SWOT Analysis?

The deciding factor is whether oncology and rare disease grow faster than Farxiga and China shrink; the first half says yes, 6 percent at CER. AstraZeneca should therefore hold core R&D at 24 percent of revenue, treat net debt as the limit on dividends and deals, and run China as a volume market with a price problem (AstraZeneca, 2026i).

The first recommendation pairs a strength with a threat. Oncology and Rare Disease, 62 percent of revenue and both growing at double digits in the half, are the only lines large enough today to replace what generic entry is taking from Farxiga and CVRM; the company's own answer, rebuilding CVRM with Baxfendy and the CSPC obesity programmes, has no sales line yet and cannot be counted on until it reports one. Core R&D at 24 percent of revenue is the mechanism, and the first half shows it working: Total Revenue grew 6 percent at CER while Farxiga fell 11 percent and China fell 5 percent (AstraZeneca, 2026i). "Diversify away from Farxiga" is too late; the diversification happened.

The second pairs two weaknesses. Net debt rose by $3,538 million in six months while operating cash inflow fell by $875 million; dividends paid were $3,288 million, the item the announcement singles out in the higher investing outflow was a $1,104 million upfront payment for licensed programmes, and capital expenditure, $1,513 million in the half, is set to rise by "approximately a third" over the year (AstraZeneca, 2026i; 2026a); the EUR 2.55 billion bond of August 2026 followed, "for general corporate purposes" (AstraZeneca, 2026l). The trade-off is between the dividend, business development and the capital programme, and a ceiling on business development alone does not settle it. Deals should be sequenced behind the readouts they depend on, under a stated net-debt ceiling that the dividend also respects, because weaker cash conversion leaves less room for the next setback than the margin suggests.

The third pairs a weakness with an opportunity. China revenue is falling because prices are set by procurement, and the company's response has been $15 billion of investment there (AstraZeneca, 2026e). Those two facts only fit together if China is measured on volume, on the medicines its four sites supply to other markets, and on the licences it sources, rather than on revenue growth.

The trade-off must be stated. The $80 billion ambition needs about 6.4 percent a year (our calculation) while 36 percent of the company shrank 5 percent in the half, so oncology and rare disease have to carry the growth and the debt service at once. The filings also set the limits of what can be said: no operating profit by therapy area, no dollar figure for the effect of volume-based procurement, and "more than twenty" readouts without saying which the ambition depends on. Writing those limits down is analysis; filling them with a guess is not.

For the same four quadrants applied to the other Form 20-F filer on this site, read our SWOT analysis of Toyota, where a powertrain mix does the job that a medicine's exclusivity period does here. More strategy samples are in our business assignment samples, and our SWOT analysis of Tesla runs the same method on a company whose 2025 numbers went the other way.

How Do You Write a SWOT Analysis Like This for Your Own Assignment?

Build it from the latest annual report and results announcement, then avoid the five faults a pharmaceutical SWOT is prone to: mixed growth rates, a core margin with no reported figure, alliance revenue counted in full, a trial called a failure, and the company's ambition written as your forecast. Each fix is below, followed by what a sample cannot supply.

1. Growth quoted at actual rates in one place and at constant exchange rates in another. AstraZeneca prints both, 9 percent as reported and 8 percent at CER for FY2025. Pick one, say which, and label every exception.
2. Core margin quoted without the reported figure. The FY2025 gap between 31 and 23 percent is $4,735 million of amortisation, impairment and restructuring; quote both and say what fills it, as weaknesses item 3 does.
3. Alliance Revenue treated as if the company kept all of it. On partnered medicines a share of the gross profit is paid away; read the gross-margin note before you count that line as growth.
4. A trial called "failed". The filing says "did not meet the primary endpoint" or "did not achieve statistical significance"; a marker knows the difference. Quote the sentence and date it.
5. The $80 billion ambition written as your forecast. It is the company's, and it "assumes successes and setbacks". Attribute it every time.

What your submission must add, because this sample stops where a graded answer starts:

• the brief's own question, answered first and returned to in the recommendations;
• two peers' figures from their own filings, because a strength is relative and this sample does not benchmark;
• a prioritisation step, TOWS or a weighted matrix, if your module teaches one; the recommendations above rank one factor and stop;
• the framework cited to an academic source, and the filings in the style your module names. Our guide to reading an annual report for a case study shows how to cite a combined annual report and Form 20-F, and our PESTEL analysis guide covers the external factors this post gives one sentence each.

Need a SWOT analysis or strategy case study on AstraZeneca or another pharmaceutical company? Message us on WhatsApp with the company, the frameworks your brief names, the word count and the deadline.

Sources

• AstraZeneca PLC (2022) AZN: Full year and Q4 2021 results. Form 6-K, 10 February 2022. SEC EDGAR (accessed 26 September 2026). Source for FY2021 Total Revenue, core and reported operating profit and margin, and the FY2021 oncology figure.
• AstraZeneca PLC (2023) Final results: full year and Q4 2022. Form 6-K, 9 February 2023. SEC EDGAR (accessed 26 September 2026). Source for FY2022 Total Revenue, core and reported operating profit and margin, and the date Alexion entered the Group's results.
• AstraZeneca PLC (2024) Final results: full year and Q4 2023. Form 6-K, 8 February 2024. SEC EDGAR (accessed 26 September 2026). Source for FY2023 Total Revenue, core and reported operating profit and margin.
• AstraZeneca PLC (2025) Final results: full year and Q4 2024. Form 6-K, 6 February 2025. SEC EDGAR (accessed 26 September 2026). Source for FY2024 Total Revenue, core and reported operating profit and margin.
• AstraZeneca PLC (2026a) Final results: full year and Q4 2025. Form 6-K, 10 February 2026. SEC EDGAR (accessed 26 September 2026). Source for FY2025 Total Revenue and its parts, the therapy-area and regional tables and the "all major geographic regions" sentence, the reconciliation of reported to core (Table 10), R&D, operating cash flow, capital expenditure and its 2026 increase, net debt at 31 December 2025, the dividend, the readout and approval counts, the FY2026 guidance and the NYSE sentence.
• AstraZeneca PLC (2026b) Annual Report and Form 20-F Information 2025. Exhibit 15.1 to the Annual Report on Form 20-F for the year ended 31 December 2025, filed 24 February 2026. SEC EDGAR (accessed 26 September 2026). Source for the five largest products, the blockbuster and multi-blockbuster counts, the pipeline counts and discontinuations, the 2030 ambition and the nine NMEs delivered against it, Alliance Revenue by medicine, the emerging-markets approvals, the US agreement and investment sentences, the US share of 2030 revenue, the Medicare price negotiation sentences on Farxiga and Calquence, the principal-risk wording in the viability statement and the Soliris litigation paragraph.
• AstraZeneca PLC (2026c) Annual Report on Form 20-F for the year ended 31 December 2025. Filed 24 February 2026. SEC EDGAR (accessed 26 September 2026). Source for US Farxiga sales in 2025 and the authorised-generic sentence.
• AstraZeneca PLC (2026d) AstraZeneca to complete direct listing on NYSE. Form 6-K, 20 January 2026. SEC EDGAR (accessed 26 September 2026). Source for the withdrawal of the ADS listing from Nasdaq and the listing dates.
• AstraZeneca PLC (2026e) AstraZeneca invests $15bn in China through 2030. Form 6-K, 29 January 2026. SEC EDGAR (accessed 26 September 2026). Source for the China commitment, the site and R&D-centre counts, the licensing count and the second-largest-market statement.
• AstraZeneca PLC (2026f) AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals. Form 6-K, 30 January 2026. SEC EDGAR (accessed 26 September 2026). Source for the CSPC terms, the headline wording and the "key growth driver" sentence on CVRM.
• AstraZeneca PLC (2026g) AstraZeneca begins trading on NYSE. Form 6-K, 2 February 2026. SEC EDGAR (accessed 26 September 2026). Source for the first trading day, the unchanged London and Stockholm listings and the "more US investors" wording.
• AstraZeneca PLC (2026h) 1st quarter results 2026. Form 6-K, 29 April 2026. SEC EDGAR (accessed 26 September 2026). Source for net debt at 31 March 2026, the first-quarter core operating margin and the first-quarter Rare Disease figure.
• AstraZeneca PLC (2026i) AstraZeneca results: H1 and Q2 2026. Form 6-K, 27 July 2026. SEC EDGAR (accessed 26 September 2026). Source for the milestone table (Table 1), the first-half tables, margins, gross-margin drivers, R&D, cash flow and the CSPC upfront, the financing lines and the net-debt reconciliation (Tables 21 and 22), net debt at 30 June 2026, the Farxiga table and its notes, the Tagrisso table notes, the headline sentence, the chief executive's statement including the Baxfendy approval, the CARDIO-TTRansform outcome and the approval count.
• AstraZeneca PLC (2026j) Update on Ultomiris Phase III trial in HSCT-TMA. Form 6-K, 27 July 2026. SEC EDGAR (accessed 26 September 2026). Source for the TMA-313 outcome sentence.
• AstraZeneca PLC (2026k) Update on eVOLVE-Lung02 Phase III trial. Form 6-K, 17 August 2026. SEC EDGAR (accessed 26 September 2026). Source for the discontinuation and the data monitoring committee's conclusion.
• AstraZeneca PLC (2026l) AstraZeneca prices a EUR 2.55 billion bond offering. Form 6-K, 25 August 2026. SEC EDGAR (accessed 26 September 2026). Source for the four tranches, their maturities and the "general corporate purposes" sentence.
• AstraZeneca PLC (2026m) Update on SERENA-4 Phase III trial. Form 6-K, 14 September 2026. SEC EDGAR (accessed 26 September 2026). Source for the SERENA-4 outcome sentence.

Filings checked for currency on 26 September 2026: AstraZeneca's submissions index on SEC EDGAR up to the Form 6-K of 23 September 2026. After the half-year results of 27 July 2026 the index holds trial-readout and approval notices (the Ultomiris TMA-313 and eVOLVE-Lung02 updates are cited above), director shareholding and voting-rights notices, the bond pricing and admission notices of 25 August and 1 September 2026, the completion of the Zegfrovy licence agreement on 1 September 2026 (an upfront payment of $600 million that falls after the half, so it is not in the June net debt), a directorate change of 1 September 2026 and the SERENA-4 update of 14 September 2026. No third-quarter 2026 results announcement had been filed; the first-half announcement is therefore the latest financial document, and FY2025 is the audited year.